Literature DB >> 24040425

Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.

Cora E Lewis1.   

Abstract

Entities:  

Year:  2011        PMID: 24040425      PMCID: PMC3769953          DOI: 10.1007/s12170-011-0159-3

Source DB:  PubMed          Journal:  Curr Cardiovasc Risk Rep        ISSN: 1932-9520


× No keyword cloud information.
  7 in total

1.  Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Authors:  Laurent Yvan-Charvet; Jelena Kling; Tamara Pagler; Hongna Li; Brian Hubbard; Tim Fisher; Carl P Sparrow; Andrew K Taggart; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

Review 2.  Anacetrapib: hope for CETP inhibitors?

Authors:  Ronen Gurfinkel; Tisha R Joy
Journal:  Cardiovasc Ther       Date:  2010-04-09       Impact factor: 3.023

3.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

Review 4.  Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.

Authors:  Alexander Thompson; Emanuele Di Angelantonio; Nadeem Sarwar; Sebhat Erqou; Danish Saleheen; Robin P F Dullaart; Bernard Keavney; Zheng Ye; John Danesh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

Review 5.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

6.  Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Authors:  Christopher P Cannon; Hayes M Dansky; Michael Davidson; Antonio M Gotto; Eliot A Brinton; A Lawrence Gould; Michael Stepanavage; Sherry Xueyu Liu; Sukrut Shah; Joseph Rubino; Patrice Gibbons; Anne Hermanowski-Vosatka; Bruce Binkowitz; Yale Mitchel; Philip Barter
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

7.  Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

Authors:  Daniel Bloomfield; Gary L Carlson; Aditi Sapre; Diane Tribble; James M McKenney; Thomas W Littlejohn; Christine McCrary Sisk; Yale Mitchel; Richard C Pasternak
Journal:  Am Heart J       Date:  2008-12-20       Impact factor: 4.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.